 | • レポートコード：D0-MOR-AP1428 • 出版社/出版日：Mordor Intelligence / 2020年4月 • レポート形態：英文、PDF、80ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥555,000 (USD3,750) | ▷ お問い合わせ |
| Team User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Corporate License | ￥1,036,000 (USD7,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、再生医療のヨーロッパ市場について調査・分析した資料で、再生医療の市場概要、動向、セグメント別市場規模、競争状況、企業情報、市場機会分析などで構成されています。 |
The key factors propelling the growth of the regenerative medicine market are the increasing adoption of stem cell technologies, gene therapies, and tissue engineering, and the technological advancements in regenerative medicine.
Stem cell technology is a rapidly developing technology that plays a major role in regenerative medicine, as it also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology. The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world.
The market is found experiencing the major technological advancements in biologics, biomaterials, stem cell technology, and tissue engineering, thus contributing to the market growth. There are also various recent advancements in regenerative medicine, including the regenerated tracheas for transplant, 3D bioprinting, stem cell treatments for vision loss, and stem cell treatments for heart repair.
The current market is also witnessing extensive R&D activities. Apart from the R&D activities being conducted by private players, there is significant involvement of academic institutions for conducting various research. Therefore, in the future, several new biotech and medtech companies are expected to come up, as the result of the current R&D endeavors across the world.
Key Market Trends
Cardiovascular Application is Expected to Cover a Large Share of the Market
Cardiac stem cell therapy holds great potential to prompt myocardial regeneration in patients with ischemic heart disease. The selection of the most suitable cell type is pivotal for its successful application. Various cell types, including crude bone marrow mononuclear cells, skeletal myoblast, and hematopoietic and endothelial progenitors, have already advanced into the clinical arena based on promising results from different experimental and preclinical studies. Different next-generation cell types are also under investigation for the treatment of the diseased myocardium.
As per European Cardiovascular Disease 2017 Statistics, by European Heart Network, over the past 2 decades, the absolute number of CVD cases has increased in Europe, with increases in the number of new CVD cases found in most countries. In 1990, the incidence of CVD was approximately 4.7 million and this number has increased to more than 5.4 million by 2015. As the incidence of CVD increases in Europe, the demand for cardiac regenerative techniques in applications like cardiac stem (CSCs) and progenitor cells (CPCs) are also expected to increase. This is expected to help the market to grow in future.
Competitive Landscape
European market is competitive players due to the presence of almost all the global players in the Regenerative Medicines Market. Many of these global players have there headquarters in European countries, which increases the accessibility of regenerative medicines throughout the Europe.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Adoption of Stem Cell Technology
4.2.2 Technological Advancements in Regenerative Medicine
4.3 Market Restraints
4.3.1 Regulatory and Ethical Issues
4.3.2 High Cost of Treatments
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Technology
5.1.1 Stem Cell Therapy
5.1.2 Biomaterial
5.1.3 Tissue Engineering
5.1.4 Other Types of Technologies
5.2 By Application
5.2.1 Bone Graft Substitutes
5.2.2 Osteoarticular Diseases
5.2.3 Dermatology
5.2.4 Cardiovascular
5.2.5 Central Nervous System
5.2.6 Other Applications
5.3 Geography
5.3.1 Europe
5.3.1.1 Germany
5.3.1.2 United Kingdom
5.3.1.3 France
5.3.1.4 Italy
5.3.1.5 Spain
5.3.1.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan Plc
6.1.2 Smith & Nephew (Osiris Therapeutics)
6.1.3 Integra Lifesciences Corporation
6.1.4 Cook Biotech Incorporated
6.1.5 Baxter International Inc.
6.1.6 Medtronic Plc
6.1.7 Thermo Fisher Scientific
6.1.8 Sigma Aldrich (a Subsidiary of Merck KGAA)
6.1.9 Becton Dickinson and Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS